How might extended-release formulations of ruxolitinib benefit patients with MF?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
How might extended-release formulations of ruxolitinib benefit patients with MF?
-
ナレーター：
-
著者：
The MPN Hub was pleased to speak with Jennifer Vaughn, The Ohio State University Comprehensive Cancer Center, Columbus, US. We asked, How might extended-release formulations of ruxolitinib benefit patients with MF?
In this interview, Vaughn discusses the potential benefits of an extended-release ruxolitinib formulation for patients with myelofibrosis, noting that ruxolitinib’s short half-life necessitates twice-daily dosing, which may reduce adherence. Vaughn highlights that an extended-release formulation, enabling once-daily dosing, may improve adherence, maintain disease control, and lessen cytopenias.
This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.